Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02569658
Other study ID # Rush TXA TSA
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2015
Est. completion date April 2017

Study information

Verified date October 2021
Source Rush University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To compare intravenous Tranexamic Acid (TXA) versus normal saline placebo to determine whether or not TXA administration reduces blood loss, decrease in hemoglobin, and rate of transfusions following anatomic and reverse total shoulder arthroplasty (TSA) surgeries.


Description:

Anatomic and reverse total shoulder arthroplasty (TSA) is associated with the risk of moderate to significant blood loss that can lead to transfusions. Average estimated blood loss has been reported in the range of 354 to 361 mL intraoperatively, not accounting for additional postoperative blood loss postoperatively in surgical drains. Transfusion rates have been reported to range from 2.4% to 9.5% in recent studies, with rates over 30% for revision cases. Tranexamic acid (TXA) is a synthetic antifibrinolytic agent that is an established method of reducing blood loss and transfusion requirement for patients undergoing total hip and knee arthroplasty. TXA can be administered intravenously, topically (intraarticularly), or orally, with most available literature addressing intravenous and topical administration. Systematic reviews and meta-analyses of the total hip and knee arthroplasty literature demonstrate approximately a 30% decrease in blood loss and 50% decrease in transfusion rate with topical or intravenous administration of TXA compared to placebo. Moreover, the literature demonstrates no increased rate of thromboembolic or other complications associated with TXA administration for hip and knee arthroplasty. Despite proven efficacy in the hip and knee arthroplasty literature, there have been no studies analyzing the ability of TXA to reduce blood loss and transfusion rate following TSA. Purpose of the study is to compare intravenous Tranexamic Acid (TXA) versus normal saline placebo to determine whether or not TXA administration reduces blood loss, decrease in hemoglobin, and rate of transfusions following anatomic and reverse total shoulder arthroplasty (TSA) surgeries. With the hypothesis that intravenous TXA will reduce blood loss following TSA.


Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date April 2017
Est. primary completion date April 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Any patient scheduled for a primary anatomic or reverse TSA Exclusion Criteria: - Allergy to TXA - Acquired disturbances of color vision - Pre-op use of anticoagulant therapy within five days before surgery - History of arterial or venous thromboembolic disease; such as DVT, PE, CVA, TIA - Pregnancy or breastfeeding - Recent MI (within 6 months of surgery) or any placement of stent regardless of time since placement - Renal impairment - Refusal of blood products - Any patient undergoing a revision TSA - Patients who decline to participate

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tranexamic Acid

Placebo


Locations

Country Name City State
United States Rush University Medical Center Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
Rush University Medical Center

Country where clinical trial is conducted

United States, 

References & Publications (9)

Alshryda S, Mason J, Sarda P, Nargol A, Cooke N, Ahmad H, Tang S, Logishetty R, Vaghela M, McPartlin L, Hungin AP. Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H). J Bone Joint Surg Am. 2013 Nov 6;95(21):1969-74. doi: 10.2106/JBJS.L.00908. — View Citation

Alshryda S, Mason J, Vaghela M, Sarda P, Nargol A, Maheswaran S, Tulloch C, Anand S, Logishetty R, Stothart B, Hungin AP. Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total knee replacement: a randomized controlled trial (TRANX-K). J Bone Joint Surg Am. 2013 Nov 6;95(21):1961-8. doi: 10.2106/JBJS.L.00907. — View Citation

Chalmers PN, Gupta AK, Rahman Z, Bruce B, Romeo AA, Nicholson GP. Predictors of early complications of total shoulder arthroplasty. J Arthroplasty. 2014 Apr;29(4):856-60. doi: 10.1016/j.arth.2013.07.002. Epub 2013 Aug 6. — View Citation

Gandhi R, Evans HM, Mahomed SR, Mahomed NN. Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis. BMC Res Notes. 2013 May 7;6:184. doi: 10.1186/1756-0500-6-184. — View Citation

Gupta AK, Chalmers PN, Rahman Z, Bruce B, Harris JD, McCormick F, Abrams GD, Nicholson GP. Reverse total shoulder arthroplasty in patients of varying body mass index. J Shoulder Elbow Surg. 2014 Jan;23(1):35-42. doi: 10.1016/j.jse.2013.07.043. Epub 2013 Sep 30. — View Citation

Ker K, Beecher D, Roberts I. Topical application of tranexamic acid for the reduction of bleeding. Cochrane Database Syst Rev. 2013 Jul 23;(7):CD010562. doi: 10.1002/14651858.CD010562.pub2. Review. — View Citation

Saltzman BM, Chalmers PN, Gupta AK, Romeo AA, Nicholson GP. Complication rates comparing primary with revision reverse total shoulder arthroplasty. J Shoulder Elbow Surg. 2014 Nov;23(11):1647-54. doi: 10.1016/j.jse.2014.04.015. Epub 2014 Jun 28. — View Citation

Shields E, Iannuzzi JC, Thorsness R, Noyes K, Voloshin I. Perioperative complications after hemiarthroplasty and total shoulder arthroplasty are equivalent. J Shoulder Elbow Surg. 2014 Oct;23(10):1449-53. doi: 10.1016/j.jse.2014.01.052. Epub 2014 Apr 18. — View Citation

Yang ZG, Chen WP, Wu LD. Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis. J Bone Joint Surg Am. 2012 Jul 3;94(13):1153-9. doi: 10.2106/JBJS.K.00873. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Post-operative Blood Loss Equated based on the patient's predicted blood volume and change in hemoglobin from the pre-operative level to the lowest post-operative level. Average of 3 days post-operatively
Secondary Number of Units Transfused Units of pack red blood cells that the patients recieved Average of 3 days post-operatively
Secondary Number of Patients Transfused Patients who received a post-op transfusion of pack red blood cells Average of 3 days post-operatively
Secondary Number of Participants With Deep Vein Thrombosis Must be diagnosed via ultrasound duplex 30 days post-operative
Secondary Number of Participants With Pulmonary Embolism Must be diagnosed via CT chest or V/Q lung scan 30 days post-operative
Secondary Number of Participants With Stroke Must be diagnosed via CT scan or MRI 30 days post-operative
See also
  Status Clinical Trial Phase
Completed NCT04588350 - Clinical Investigation Evaluating a New Autotransfusion Device in Cardiac Surgery N/A
Completed NCT05426564 - Exploratory Assessment of the Quantra® System in Adult ECMO Patients
Active, not recruiting NCT05492214 - The Effect of Time Window for Umbilical Cord Clamping During Cesareans on Offspring Hemoglobin and Maternal Blood Loss N/A
Withdrawn NCT05518279 - Early Administration Of Tranexamic Acid And Acute Blood Loss In Patients With Hip Fractures Phase 3
Enrolling by invitation NCT02910115 - Cooling the Uterus in C-section After Dysfunctional Labor N/A
Completed NCT01048658 - Sevoflurane as an Anesthetic During Dilation and Evacuation Procedures Phase 4
Terminated NCT02908516 - Safety and Efficacy of Oral TXA in Reducing Blood Loss and Transfusion in Hip Fractures Phase 4
Completed NCT04089865 - Oral Versus Intravenous Tranexamic Acid Phase 4
Recruiting NCT06403163 - Transfusion Surveillance in Anaesthesia
Recruiting NCT02265562 - Rectal Misoprostol and Blood Loss During Abdominal Hysterectomy Phase 3
Completed NCT02083809 - Effects of Oxytocin on Bleeding Outcomes During Dilation and Evacuation N/A
Completed NCT02312440 - Comparison of Topical and Intravenous Tranexamic Acid in Total Hip Arthroplasty Phase 3
Completed NCT01895101 - The Effect on Blood Loss of Topical and Intravenous Tranexamic Acid in Cardiac Surgery Patients Phase 4
Completed NCT00990288 - The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery Phase 4
Completed NCT01099475 - Effect of Intermittent Pedicle Clamping on Hepatocellular Injury During Liver Surgery N/A
Completed NCT03365999 - Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement. Phase 2
Recruiting NCT05550623 - Pneumatic Tourniquet Versus no Tourniquet in Transfemoral Amputation N/A
Completed NCT05012202 - Validating a New Point-of-care Device for Estimation of Blood Count in Pregnant Women
Completed NCT02311309 - Epidemiology of Severe Peroperative Bleeding During Scheduled Surgery N/A
Withdrawn NCT01712971 - Reduced Intra-operative Blood Loss in Pancreaticoduodenectomy for Pancreatic or Peri-ampullary Tumors; Monocentric Trial on Standard Open Versus Minimally Invasive Surgery N/A